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Introduction: Guidelines suggest that all patients with choledocholithiasis should have a coagulation
screen prior to endoscopic retrograde cholangiopancreatography (ERCP). This study aims to establish the
incidence of deranged coagulation in such patients and its relationship with bleeding complications.
Methods: Analysis of consecutive patients undergoing ERCP procedures at two NHS sites was under-
taken. Exclusion criteria were anti-coagulation use, bleeding disorders or incomplete data. Demographic
data, pre-procedure bilirubin and prothrombin time (PT), ERCP procedural information, and bleeding
complications were recorded for each. The cohort was divided into jaundice and non-jaundiced groups.
Statistical analysis was performed using the student's t-test, Chi-squared test and Fisher's exact test.
Results: 793 patients (419 jaundiced; 374 non-jaundiced) were included. PT was signiﬁcantly higher in
the jaundiced group (greater by 2 (1.35e2.64) seconds; p < 0.001). PT was prolonged in 26.7 per cent of
the jaundiced group; 28 patients (6.7 per cent) had a PT of >16.8 s 5.9 per cent of the non-jaundiced
group had prolonged PT, with 1 patient having a PT >16.8 s. There were 5 major, and 32 minor
bleeding complications with no differences between groups. In those with abnormal coagulation, only 1
minor bleeding complication occurred in a jaundiced patient. Discussion: Normal pre-ERCP bilirubin was
99.7% (98.5e100) sensitive to predict a PT <16.8 s. Cost savings of £14,350 could have been achieved with
judicial use of coagulation screening. Conclusion: Pre-ERCP coagulation screening should only be
indicated in patients with a raised bilirubin or individuals on anticoagulation therapy or with a history of
bleeding diathesis.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gallstone disease is endemic in the UK population, as in other
Western countries, with 10e15 per cent of the adult population
having gallstones [1]. Presentation to hospital due to the sequelaerichardjohn.egan@wales.nhs.
by Elsevier Ltd. All rights reservedof gallstones is a common occurrence, with over 150,000 hospital
admissions in England alone in 2012e2013 [2]. Subsequent inves-
tigation often reveals evidence of common bile duct (CBD) stones or
choledocholithiasis. Guidelines on the management of CBD stones
have been established by the British Society of Gastroenterology
(BSG) [3]. If patients have biliary symptoms and there is evidence of
CBD stones following investigation, it is recommended that such
calculi are extracted to prevent further complications. However, In
order to minimise the number of patients undergoing invasive.
Table 1
Comparison of biochemically jaundiced and non-jaundiced groups.
Non-jaundiced Jaundiced t-test (except
Chi-squared)
Number of patients 374 419
Male-to-female ratio 137: 237 (36.6 per
cent male)
194: 225 (46.3 per
cent male)
P ¼ 0.007
Mean ± SD age 68.9 ± 16.1 years 66.9 ± 17.0 years P ¼ 0.090
Mean ± SD bilirubin
(mmol/L)
10.5 ± 4.8 126.9 ± 113.0 P < 0.001
Mean ± SD PT
(seconds)
11.0 ± 1.2 13.0 ± 6.3 P < 0.001
Mean coagulation
screens/patient
2.1 ± 3.5 2.8 ± 2.7 P < 0.001
PT, prothrombin time; SD, standard deviation.
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that endoscopic retrograde cholangio-pancreatography (ERCP) be
reserved for those patients in whom it is likely that such an
extraction intervention will be required, and should not be used as
a diagnostic test [3].
For those patients who are likely to require biliary sphincter-
otomy, the BSG guidelines suggest that all have a prothrombin
time (PT)/international normalised ratio (INR) coagulation screen
and a full blood count (FBC) check within 72 h of the procedure
(Grade III evidence/Grade B recommendation) [3]. Previous BSG
guidance suggested that these tests should be performed within
24 h of the procedure if possible [4]. These 2006 guidelines
postulate that an INR of <1.2 and a platelet count of >50,000/
mm3 should be considered safe for a sphincterotomy [4]. Other
groups have suggested that a platelet count of <80,000/mm3 and/
or a PT >2 s above the normal range, should be considered a
coagulopathy [5]. The availability of pre-operative bilirubin and
PT levels has also been suggested by the National Conﬁdential
Enquiry into Patient Outcome and Deaths (NCEPOD), following a
2004 investigation [6]. Prothrombin time has been the suggested
coagulation test of choice prior to ERCP as its main uses include
the detection of acquired bleeding disorders, such as liver disease,
vitamin K deﬁciency and disseminated intravascular coagulation
(DIC), in addition to its role in monitoring of anticoagulant
therapies [7].
Given that the incidence of bleeding diathesis in the general
population is low and that routine coagulation testing is not per-
formed in patients undergoing elective surgery provided their
platelet count is normal, it is debatable whether coagulation
screening tests add anything to the management of non-jaundiced
patients undergoing ERCP. In addition, prothrombin time will
remain within normal levels in the presence of the more common
hereditary coagulopathies such as von Willebrand disease, and
Haemophilia A and B [8]. This study examines the incidence of
deranged coagulation and bleeding complications in patients with
and without evidence of biochemical jaundice prior to therapeutic
ERCP.
2. Methods
We performed a retrospective analysis of consecutive ERCP
procedures undertaken at the University Hospital of Wales, Cardiff
(Site A), and the Princess ofWales Hospital, Bridgend (Site B), over a
16 month period. All information was gathered from the prospec-
tively maintained clinical intranet systems in each hospital board.
For each patient, the immediate pre-procedure bilirubin and PT
(seconds) was recorded, along with demographic data. For those
patients with multiple pre-ERCP coagulation screens due to a
prolonged admission, for example, the greatest PT stated was
recorded. This therefore highlighted the true incidence of abnormal
coagulation screens, as any patients who had potentially under-
gone clinical correction of an abnormal clotting screen were iden-
tiﬁed. The technical nature of the ERCP procedure and the ﬁnal
diagnosis in each case was also documented.
The local policy for ERCP is that an INR of <1.5 is required pre-
operatively for therapeutic ERCP, including spincterotomy. A PT of
16.8 s (equivalent to an INR of 1.5) was used as our cut-point during
this analysis. Patients were excluded if they were admitted on
warfarin therapy, had a known coagulopathy or had no docu-
mented PT and/or serum bilirubin during that admission. Normal
distribution of data was established via histogram plots and, where
necessary, QeQ plots. Statistical analysis was performed using the
Student's t-test and Chi Squared test. Fisher's exact test was utilised
if one or more group contained 5 or less patients. A P value of
<0.050 was considered statistically signiﬁcant.Cost analysis was based on the local tariff price for performing a
coagulation screen. Jaundice was deﬁned as any bilirubin above the
normal range (>21 mmol/L) without a documented history of
hyperbilirubinaemia (e.g. Gilbert's syndrome). In these rare cases,
jaundice was deﬁned as a bilirubin above the documented baseline
bilirubin. Major bleeding was deﬁned as haemorrhage which
required a blood transfusion, a repeat therapeutic endoscopic or
surgical/radiological intervention, or which resulted in a fatality.
Minor bleeding was deﬁned as any bleeding complication, which
either required therapeutic intervention to control bleeding during
the primary procedure or resulted in a period of prolonged obser-
vation at the request of the endoscopist. Post-procedure haema-
temesis or melaena was also classiﬁed as minor providing none of
the criteria for major bleeding were met.3. Results
A total of 898 procedures were performed during the study
period, over the two sites. Of these, 105 patients were excluded (60
on warfarin, 2 with inherited coagulopathies and 43 with no bili-
rubin/PT recorded. Therefore, 793 patients were included in the
ﬁnal cohort. This cohort was divided into two groups for analysis:
jaundiced (n ¼ 419) and non-jaundiced (n ¼ 374). Patient de-
mographics, serum bilirubin and PT are summarised in Table 1.
The mean (95% conﬁdence interval) PT was signiﬁcantly higher
in the jaundiced group (greater by 2.0 (1.35e2.64) seconds,
P < 0.001, Student's t-test). Furthermore, 26.7 per cent (n ¼ 112) of
the jaundiced group had a prolonged PT (above the normal range)
and 28 of these (6.7 per cent) had a PT of >16.8 s (equivalent to an
INR 1.5). In contrast, 5.9 per cent (n ¼ 22) of non-jaundiced pa-
tients had a raised PT, (P < 0.001 when compared with jaundiced
group; Chi-squared test). Only 1 of these patients in the non-
jaundiced group had a PT >16.8 s (P < 0.001 compared with the
jaundiced group; Fisher's exact test).
Major bleeding events occurred in 2 patients (0.5 per cent) in
the jaundiced group, resulting in the death of one patient. Major
bleeding occurred in 3 (0.8 per cent) non-jaundiced patients but
there were no mortalities. Minor bleeding events occurred in 4.3
per cent (18 patients) of jaundiced patients and 3.7 per cent (14
patients) of the non-jaundiced group. Of those with bleeding
complications, only one patient in the jaundiced group had
abnormal coagulation pre-procedure and this was classed as a
minor bleeding complication (pre-ERCP bilirubin 330 mmol/L, PT
27.5 s). None of the bleeding complications in the non-jaundiced
group were associated with abnormal pre-procedure coagulation
screening. There was no statistical difference in bleeding rates be-
tween groups.
A total of 793 coagulation screens were performed in the non-
jaundiced group, at a total cost of approximately £7490,
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£11,370 in the jaundiced group. A between groups comparison of
the breakdown of ERCP diagnoses and procedures is given in
Table 2.
There were no statistically signiﬁcant differences between the
two study sites in terms of mean patient age, male-to-female ratio,
mean cohort pre-ERCP bilirubin or prothrombin time, bleeding
complications or proportion of patients with abnormal coagulation
pre-ERCP. This was true when comparing jaundiced with non-
jaundiced sub-groups and combined groups between sites.
Of note, signiﬁcantly more pre-procedure coagulation screens
per patient were performed in site A than site B for both the
jaundiced group (mean 3.1 versus 2.4; p¼ 0.009) and the combined
jaundiced and non-jaundiced groups (2.7 versus 2.1; p ¼ 0.009).
The four consultants responsible for the ERCP procedures per-
formed (or supervised) a total of 274, 237, 190, and 102 procedures
each, respectively.4. Discussion
ERCP is now a widely performed procedure with a variety of
therapeutic applications. Approximately 700 ERCP procedures are
performed per annum across the two study sites. Guidelines exist
to guide healthcare professionals in using this treatment entity
judiciously whilst attempting to mitigate its associated risk of
morbidity and mortality.
Several reports have shown that complication rates following
biliary sphincterotomy correlate with the annual workload of the
endoscopist or endoscopy department [3,5]. Each of the four con-
sultants undertaking ERCP as part of this study performed in excess
of 100 procedures during the study period, even before considering
the 105 patients excluded from the statistical analysis. The thera-
peutic goal of ERCP was achieved in 93.4 per cent of our patients,
with the procedure abandoned in 52 patients. These ﬁgures
comfortably fall within guidelines, which suggest that cannulation
rates of >80 per cent should be achieved in units offering ERCP, and
compares favourably to a large-scale audit of practice that found
completion of intended treatment rates of 70.4 per cent, with 77
per cent of endoscopists evaluated achieving cannulation rates of
>80 per cent [3,9,10]. It is likely, therefore, that the complication
rates presented here are representative of typical practice, and not
inﬂuenced by learning curves or low volume practice.
There are several well documented complications associated
with ERCP, although the overall incidence of each is low. The overallTable 2
Comparison of diagnosis and ERCP procedure between groups.
Jaundiced
(n ¼ 419)
Non-
jaundiced
(n ¼ 374)
Between group
differencea
Total
(n ¼ 793)
Diagnosis
CBD stones/gallstone
pancreatitis
193 207 P ¼ 0.584 400
Cholangitis 37 33 P ¼ 0.382 70
Malignancy/obstructive
jaundice
169 83 P < 0.001 252
Bile leak 11 32 P ¼ 0.006 43
Other 9 19 P ¼ 0.153 28
Procedure
Sphincterotomy ± stent 219 171 P < 0.001 390
Stent/stent removal/
stent change
142 148 P ¼ 0.485 290
Cholangiogram only 19 24 P ¼ 0.807 43
Abandoned 39 31 P ¼ 0.169 70
CBD, common bile duct.
a Chi-squared test in each case.complication rate after sphincerotomy is approximately 5 per cent,
with severe complications affecting only 1 per cent [4]. A pro-
spective UK review of more than ﬁve thousand ERCPs reported an
overall complication rate of 5.1 per cent (268 of 5264 procedures)
[9]. Gastrointestinal haemorrhage has been reported in 0.7e2.0 per
cent of patients, and the incidence is approximately 1.5 per cent for
those patients having sphincterotomy as part of a therapeutic ERCP,
with a mortality of 0.1 per cent in such patients [3,4]. This overall
complication rate has improved over time, with a large US study
into complications following sphincterectomy from 1996, reporting
a rate of 9.8 per cent (229 of 2347 patients), with haemorrhage
occurring in 2 per cent (48) of patients [5]. The haemorrhagic
complication rate in our cohort was 4.7 per cent (37 of 793 pa-
tients), with major bleeding complications occurring in 5 patients
(0.6 per cent). These complication rates compare well with the
literature, with the slightly elevated overall bleeding rate likely to
be due to a rigorous reporting system including minor complica-
tions that required no post-procedure intervention.
Post-sphincterotomy bleeding is usually self limiting and is
rarely life threatening unless the patient has a bleeding diathesis
[4]. Refractory bleeding can be treated medically, endoscopically,
surgically or via interventional radiology with selective embolisa-
tion. A large scale UK review found that mortality secondary to
bleeding occurred within 30 days in 4 of the 4561 (0.09 per cent)
patients included in the study, with two of these cases being
complicated by cholangitis [9]. The only signiﬁcant correlate with
mortality in that study was ASA grade of the patient, whilst 62 per
cent of fatal complications (all cause) occurred in those aged over
75 [9]. There was one in-hospital death following ERCP in this
cohort, with the cause of death thought to be related to the
sequelae of a large post-procedure bleed (mortality rate 0.1 per
cent).
Despite the relative rarity of bleeding-related complications, all
patients routinely undergoing ERCP are rigorously screened for
coagulation abnormalities, irrespective of the clinical likelihood
that such abnormalities exist. A review by the British Committee
for Standards in Haematology (BCSH) has stated that: ‘Indiscrim-
inate coagulation screening prior to surgery or other invasive
procedures to predict post-operative bleeding in unselected pa-
tients is not recommended’ (Grade B recommendation based on
level III evidence) [7]. Following a literature review of relevant
studies, they reported that the positive predictive value and like-
lihood ratio for coagulation tests indicate that they are poor pre-
dictors of bleeding [7]. In our series only one minor bleeding
complication occurred in the 134 patients with abnormal coagu-
lation parameters (0.7 per cent) suggesting that such abnormal-
ities confers low risk for subsequent bleeding, especially with
readily available treatments to correct such abnormalities. Of
much more importance in terms of predicting those at risk of
bleeding, is a comprehensive bleeding history to include family
history, previous excessive bleeding following trauma or surgery,
anti-coagulant or anti-platelet medication use and co-morbidities
associated with coagulopathy. The BCSH state that patients with a
negative bleeding history do not require routine coagulation
screening prior to surgery [7]. It is important to bear in mind that
PT, and similar coagulation tests, were designed as diagnostic tests
to conﬁrm a suspicion of a bleeding disorder, rather than a
screening test for conditions with a low incidence in the general
population [7]. In addition, it must also be remembered that by
deﬁnition, 2.5 per cent of the ‘normal’ population will have pro-
longed PT results [7].
Coagulopathy, associated with both prolonged biliary obstruc-
tion and parenchymal liver disease, is a well-recognised risk factor
for haemorrhage following therapeutic endoscopic procedures, and
has been described in several studies [3,4,11]. This coagulopathy is
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the many coagulation factors, anticoagulants, and compounds of
the ﬁbrinolytic system that are produced in the liver [11]. One of the
main underlying pathological processes underpinning this coa-
gulopathy is the poor absorption of vitamin K, due to the absence of
bile in the gastrointestinal tract [7]. Despite an elevated bilirubin
being associated with a signiﬁcantly increased rate of abnormal
coagulation screens in this series, there was no difference in
bleeding complications between the jaundiced and non-jaundiced
groups.
It is interesting to note that contradictory evidence, suggesting
an increased incidence of post-sphincterotomy haemorrhage in
patients with normal clotting parameters, has been reported in the
literature [3]. In line with our ﬁndings, other studies looking at a
variety of invasive procedures, found no signiﬁcant differences in
major bleeding rates between patients with normal PT values pre-
procedure, and abnormal PT values [12].
These data suggest that those who are at increased risk of a
prolonged PT can be predicted by examination of their admission
liver function tests (LFTs), speciﬁcally their serum bilirubin level. In
this cohort 419 patients (52.8 per cent) had an abnormal bilirubin
level prior to ERCP, with a mean (±standard deviation) serum
concentration of 127 ± 113 mmol/L. An elevated bilirubin has a
sensitivity (95% conﬁdence interval [95%CI]) of 26.7 (22.6e31.2) per
cent to predict an abnormal PT, and 6.7 (4.5e9.5) per cent to predict
a PT of >16.8 s (INR 1.5) in our study. Despite this apparently low
sensitivity, 96.5 (82.2e99.4) per cent of those with a PT >16.8 will
have an elevated bilirubin and this high positive predictive value
reinforces the ﬁnding that grossly deranged coagulation is
exceedingly rare in the absence of jaundice. Conversely, those with
normal LFTs are unlikely to have been subjected to the pathological
processes required to result in deranged coagulation. In this cohort
a normal bilirubin had a speciﬁcity (95%CI) of 94.1 (91.2e96.3) per
cent to predict a normal PT, and 99.7 (98.5e100) per cent to predict
a PT of <16.8 s. Therefore performing expensive haematological
tests in such patients is unlikely to provide signiﬁcant additional
information or alter patient management.
A report on ERCP practice in England found that serum bilirubin
was elevated in 68 per cent of patients undergoing a ﬁrst ERCP
procedure [9]. This is likely to be an overrepresentation, however,
as 20 per cent of that cohort did not have a bilirubin level docu-
mented pre-procedure and are likely to represent a largely non-
jaundiced sub-group of patients [9]. In this study 4539 of 5264
(13.8 per cent) patients had no pre-procedure PT documented [9].
Only 43 (4.8 per cent) of our patients had no documented bilirubin
or prothrombin time prior to undergoing their procedure.
Patients taking anti-coagulants are not included in our study as
it is obvious that in such cases, assessment of coagulation status is a
key aspect of pre-ERCP management requiring a minimum of an
INR check. There is guidance available to aid in the management of
patients taking anti-coagulation and anti-platelet therapy in such
clinical scenarios. In general, therapeutic ERCP, including sphinc-
terotomy, can be performed in patients taking aspirin, non-
steroidal anti-inﬂammatory drugs, or on low-dose heparin [3,13].
Those on anti-coagulation, such as warfarin should stop treatment
several days before the procedure, time allowing, and be converted
to intra-venous unfractionated heparin during this time if they are
considered at high risk of thromboembolism [3,13]. Those on
alternative anti-platelet agents, such as clopidogrel, should ideally
stop taking their medication 7e10 days pre-ERCP [3,13]. It is
interesting that previous guidelines have suggested a minimum
safe platelet count for sphincterotomy, as such a ﬁgure does not
give an objective measurement of platelet function [4].
The mean number of pre-procedure PT tests per patient in the
non-jaundiced group was 2.1, with an average total cost of £20.03per patient. A total cost saving of £7493 would be achieved in our
cohort if none of the patients in the non-jaundiced group had un-
dergone PT evaluation pre-operatively. In addition, a total of 1184
coagulation screens were performed in the jaundiced group of
patients. Assuming that all jaundiced patients should undergo an
initial PT evaluation, and those with a PT of >16.8 s a repeat test
following correction, this corresponds to an excess of 737 tests at a
cost of £6855. Judicial use of coagulation screening in our cohort
would potentially lead to cost savings amounting to £14,348, or
£18.09 for each patient undergoing ERCP. It is estimated that 48,000
ERCP procedures are performed in the UK per annum [9,10].
Assuming a similar proportion of non-jaundiced patients and a
similar mean number of procedures per patient as seen in our
cohort, an estimated annual cost saving of approximately £868,500
could be achieved nationally.
5. Conclusion
We conclude that pre-procedure coagulation screening in pa-
tients undergoing ERCP is only indicated in patients with a raised
bilirubin. Furthermore, continuing to routinely perform coagula-
tion screens in all patients places an unnecessary burden on re-
sources, both in terms of laboratory costs and the inevitable
postponement of some procedures when coagulation tests have
been omitted.
In order to identify patients who require a coagulation screen,
we advocate making speciﬁc enquiries about personal or family
bleeding tendency and medication usage, as part of the pre-
procedural checks.
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